Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study reveals hidden toll of vitiligo on chinese patients

NCT ID NCT07058051

Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how vitiligo affects people in China, including their treatments and daily life. Researchers observed 100 patients to measure the disease's impact on their skin and quality of life. The goal was to better understand the real-world burden of this condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Jul 2025

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Chinese patients with non-segmental vitiligo and 5≤T-VASI\<50 will be included. The NSV patients will be consecutively enrolled via convenience sampling in this study.

Ages

12 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female patients, age ≥ 12. * Chinese patients meet the diagnosis of Non-Segmental Vitiligo (NSV) and 5≤ Total Vitiligo Area Scoring Index (T-VASI\<50) with or without facial involvement. * Medical history available within the last 6 months. * Ability to understand the questionnaires, with parental support as required for adolescents (between ≥ 12 and \< 18 years of age at inclusion visit). * Willing to provide a patient authorization form to use and disclose personal health information (or informed consent, where applicable) to participate in the study; for adolescent subjects, authorization and/or consent will be provided by a parent or legal guardian, where applicable. Exclusion Criteria: * Unable or unwilling to comply with study requirements and electronic Patient-Reported Outcome (ePRO) collection. * Segmental or localized vitiligo. * Greater than 33% leukotrichia in areas of vitiligo on the face or on the body. * History of active skin disease other than vitiligo that could interfere with the assessment of vitiligo. * Patients who are participating in interventional clinical trial(s) at time of study visit. * Patients who are currently receiving treatment with any investigational drug/device/intervention or have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) prior to enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-segmental vitiligo are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-segmental vitiligo

Contacts and locations

Locations

  • Dermatology Hospital of Southern Medical University /ID# 276921

    Guangzhou, Guangdong, 510091, China

  • Shandong Dermatological Hospital /ID# 276918

    Jinan, Shandong, 250022, China

  • Suzhou Municipal Hospital /ID# 276948

    Suzhou, Jiangsu, 215002, China

  • Wuhan Integrated TCM & Western Medicine Hospital（Wuhan No.1 Hospital) /ID# 276919

    Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.